secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2023-03-07T23:59:59+00:00
Accession:  0000950170-23-006349
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA reports cash $373.1M, net loss $58.7M; darovasertib data mid-2023
------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $373.1M as of Dec 31, 2022; sufficient to fund operations into 2026.
- Net loss $58.7M for FY2022 vs $49.8M in FY2021; Q4 collaboration revenue $4.0M vs $3.0M.
- Targeting mid-2023 clinical efficacy update for darovasertib/crizotinib in ~20 first-line MUM patients; goals: >20% ORR, >5 months mPFS.
- First-patient dosing of IDE161 (PARG) in Q1 2023; IND submission for Pol Theta Helicase in Q2 2023 with GSK.
- Discontinuing IDE397+chemo cohorts; prioritizing IDE397/AMG193 combination with Amgen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023006349/0000950170-23-006349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023006349/idya-20230307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer